Condition
Drug Intolerance
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 67/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 4 (1)
Trial Status
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03052218Not ApplicableTerminatedPrimary
Evaluation of Pupillometry for cyp2d6 Phenotyping in Children Treated With Tramadol
NCT03280368Completed
Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
NCT02984293Phase 4CompletedPrimary
Statin Immune Study
Showing all 3 trials